Paricalcitol changed hormone levels in dialysis patients, with an uncertain later FGF23 response
PTH fell during treatment, while FGF23 rose early and later showed no statistically clear difference from baseline. The results do not establish clinical benefit.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
PTH was lower at 6 and 12 weeks than at baseline. FGF23 rose at 6 weeks; at 12 weeks, its difference from baseline was not statistically significant. Doses were adjusted according to PTH response, so this time pattern does not show that a particular dose is superior or safer.
The study was short and had incomplete patient data. This abstract-based account also has a comparator ambiguity: the results report baseline comparisons, while the conclusion describes a placebo comparison without giving its numerical results.
Hormone outcomes
Researchers measured parathyroid hormone (PTH) and fibroblast growth factor (FGF23) during paricalcitol treatment in dialysis patients. These blood hormone levels describe biological responses; the abstract does not establish effects on symptoms or other patient outcomes.
Why the dosing pattern matters
Treatment doses changed in response to hormone measurements over time. This limits conclusions about starting doses from the reported time course; the abstract does not present a direct comparison of alternative starting-dose strategies.
The original publication
Dose response of PTH and FGF23 to paricalcitol in patients with end-stage renal failure on chronic intermittent hemodialysis.
Mussmaecher N, Mitzner S, Haas C et al.
Clin Nephrol · 2026
- PubMed ID
- 41378845
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.